Inhaled fluticasone <font color="red">reduces_1</font> <font color="red">sputum_3</font> <font color="red">inflammatory_3</font> <font color="red">indices_3</font> in severe <font color="red">bronchiectasis_1</font> <font color="red">._1</font> 
<br>
<br> Although corticosteroid therapy might be <font color="red">clinically_1</font> <font color="red">beneficial_1</font> for <font color="red">bronchiectasis_2</font> <font color="red">,_2</font> very little is known of its effects on the <font color="red">inflammatory_2</font> <font color="red">and_2</font> <font color="red">infective_2</font> <font color="red">markers_2</font> <font color="red">in_2</font> <font color="red">bronchiectasis_2</font> <font color="red">._2</font> We have therefore performed a double - blind , placebo - controlled study to evaluate the effects of a 4-wk administration of <font color="red">inhaled_1</font> <font color="red">fluticasone_1</font> <font color="red">in_1</font> <font color="red">bronchiectasis_2</font> <font color="red">._2</font> Twenty - four patients ( 12 female ; mean age 51 yr ) were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo . At each visit , <font color="red">spirometry_1</font> <font color="red">,_1</font> <font color="red">24-h_2</font> <font color="red">sputum_2</font> <font color="red">volume_2</font> <font color="red">,_2</font> <font color="red">sputum_2</font> <font color="red">leukocyte_2</font> <font color="red">density_2</font> <font color="red">,_2</font> <font color="red">bacterial_2</font> <font color="red">densities_2</font> <font color="red">,_2</font> <font color="red">and_1</font> <font color="red">concentrations_2</font> <font color="red">of_2</font> <font color="red">interleukin_2</font> <font color="red">(_2</font> <font color="red">IL)-1beta_2</font> <font color="red">,_2</font> <font color="red">IL-8_2</font> <font color="red">,_2</font> <font color="red">tumor_2</font> <font color="red">necrosis_2</font> <font color="red">factor_2</font> <font color="red">-_2</font> <font color="red">alpha_2</font> <font color="red">(_2</font> <font color="red">TNF_2</font> <font color="red">-_2</font> <font color="red">alpha_2</font> <font color="red">)_2</font> <font color="red">,_2</font> <font color="red">and_1</font> <font color="red">leukotriene_2</font> <font color="red">B4_2</font> <font color="red">(_1</font> <font color="red">LTB4_1</font> <font color="red">)_1</font> were determined . There was a significant ( p < 0.05 ) decrease in <font color="red">sputum_4</font> <font color="red">leukocyte_4</font> <font color="red">density_4</font> <font color="red">and_3</font> <font color="red">IL-1beta_4</font> <font color="red">,_4</font> <font color="red">IL-8_4</font> <font color="red">,_4</font> <font color="red">and_3</font> <font color="red">LTB4_4</font> after fluticasone treatment . The fluticasone group had one and the placebo group three <font color="red">episodes_1</font> <font color="red">of_1</font> <font color="red">exacerbation_4</font> <font color="red">._4</font> There were no significant changes in <font color="red">spirometry_4</font> ( p > 0.05 ) or any <font color="red">reported_1</font> <font color="red">adverse_4</font> <font color="red">reactions_4</font> in either group . The results of this study show that high - dose fluticasone is <font color="red">effective_1</font> <font color="red">in_1</font> <font color="red">reducing_1</font> <font color="red">the_1</font> <font color="red">sputum_4</font> <font color="red">inflammatory_4</font> <font color="red">indices_4</font> <font color="red">in_3</font> <font color="red">bronchiectasis_3</font> <font color="red">._3</font> Large - scale and long - term studies are indicated to evaluate the effects of inhaled steroid therapy on the <font color="red">inflammatory_2</font> <font color="red">components_2</font> <font color="red">in_2</font> <font color="red">bronchiectasis_3</font> <font color="red">._3</font>